Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Ovid Therapeutics files $250M mixed securities shelf  06:44
11/13/20
11/13
06:44
11/13/20
06:44
OVID

Ovid Therapeutics

$5.42 /

+0.36 (+7.11%)

 
ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

10/26/20 Citi
Citi opens positive catalyst watch on Ovid Therapeutics
08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

Earnings
Ovid Therapeutics reports Q3 EPS (28c), consensus (36c) » 16:51
11/12/20
11/12
16:51
11/12/20
16:51
OVID

Ovid Therapeutics

$5.42 /

+0.36 (+7.11%)

Reports Q3 revenue…

Reports Q3 revenue $6.91M, consensus $80,000. "We are very pleased with the progress made on our pipeline this quarter, which was highlighted by encouraging results from both the ELEKTRA and the ARCADE Phase 2 trials of OV935," said Jeremy Levin, chairman and CEO of Ovid Therapeutics. "We look forward to advancing OV935 into a Phase 3 program for Dravet syndrome and Lennox-Gastaut syndrome next year after our end-of-phase 2 meeting with FDA. We are continuing to explore further clinical development opportunities in CDKL5 deficiency disorder, and Dup15q syndrome. Additionally, we remain on track to report topline data for the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome this quarter. Pending a successful NEPTUNE readout, OV101 has the potential to become the first-ever treatment approved for Angelman syndrome, a disorder affecting some 500,000 patients worldwide."

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

10/26/20 Citi
Citi opens positive catalyst watch on Ovid Therapeutics
08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

OVID Ovid Therapeutics
$5.42 /

+0.36 (+7.11%)

Over a month ago
Recommendations
Citi opens positive catalyst watch on Ovid Therapeutics » 14:25
10/26/20
10/26
14:25
10/26/20
14:25
OVID

Ovid Therapeutics

$5.21 /

-0.14 (-2.62%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz opened a positive catalyst watch on Ovid Therapeutics ahead of the company's report of topline results from the Phase NEPTUNE trial of OV101 in Angelman Syndrome patients, which he expects some time in Q4 and no later than late November given when the study completed enrollment. The analyst, who continues to view the "regulatory bar for OV101 approval in Angelman as low," believes the stock could trade up 50% to 75% following positive data, or could trade down more than 40% on negative data. Nochomovitz keeps a Buy rating and $10 price target on Ovid shares.

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.21 /

-0.14 (-2.62%)

OVID Ovid Therapeutics
$5.21 /

-0.14 (-2.62%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
OVID Ovid Therapeutics
$5.21 /

-0.14 (-2.62%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.21 /

-0.14 (-2.62%)

OVID Ovid Therapeutics
$5.21 /

-0.14 (-2.62%)

Conference/Events
Ovid Therapeutics to hold an educational webinar » 12:25
10/22/20
10/22
12:25
10/22/20
12:25
OVID

Ovid Therapeutics

$5.31 /

+0.1 (+1.92%)

Management holds an…

Management holds an Educational Webinar on Angelman Syndrome and OV101 Development Program on October 22 at 1 pm. Webcast Link

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.31 /

+0.1 (+1.92%)

OVID Ovid Therapeutics
$5.31 /

+0.1 (+1.92%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
OVID Ovid Therapeutics
$5.31 /

+0.1 (+1.92%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.31 /

+0.1 (+1.92%)

OVID Ovid Therapeutics
$5.31 /

+0.1 (+1.92%)

Conference/Events
Ovid Therapeutics to hold an educational webinar » 04:55
10/22/20
10/22
04:55
10/22/20
04:55
OVID

Ovid Therapeutics

$5.21 /

-0.13 (-2.43%)

Management holds an…

Management holds an Educational Webinar on Angelman Syndrome and OV101 Development Program on October 22 at 1 pm. Webcast Link

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.21 /

-0.13 (-2.43%)

OVID Ovid Therapeutics
$5.21 /

-0.13 (-2.43%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
OVID Ovid Therapeutics
$5.21 /

-0.13 (-2.43%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.21 /

-0.13 (-2.43%)

OVID Ovid Therapeutics
$5.21 /

-0.13 (-2.43%)

Conference/Events
Ovid Therapeutics to hold an educational webinar » 13:36
10/16/20
10/16
13:36
10/16/20
13:36
OVID

Ovid Therapeutics

$5.61 /

-0.075 (-1.32%)

Management holds an…

Management holds an Educational Webinar on Angelman Syndrome and OV101 Development Program on October 22 at 1 pm. Webcast Link

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.61 /

-0.075 (-1.32%)

OVID Ovid Therapeutics
$5.61 /

-0.075 (-1.32%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
OVID Ovid Therapeutics
$5.61 /

-0.075 (-1.32%)

  • 25
    Aug
OVID Ovid Therapeutics
$5.61 /

-0.075 (-1.32%)

OVID Ovid Therapeutics
$5.61 /

-0.075 (-1.32%)

Hot Stocks
Ovid Therapeutics announces results from ARCADE, ENDYMION studies of soticlestat » 08:04
09/30/20
09/30
08:04
09/30/20
08:04
OVID

Ovid Therapeutics

$5.98 /

+0.09 (+1.53%)

Ovid Therapeutics…

Ovid Therapeutics announced results from the ARCADE and ENDYMION studies of soticlestat in patients with developmental and epileptic encephalopathies, or rare epilepsies. The Phase 2 ARCADE study is a signal-finding open-label pilot study of soticlestat in patients with CDKL5 deficiency disorder and Dup15q syndrome, two highly refractory rare epilepsies that have no approved treatment options, while ENDYMION is an open-label long-term extension study with soticlestat. All patients who completed the ARCADE study opted to roll over into ENDYMION. Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase being developed in collaboration with Takeda Pharmaceutical Company Limited. Together, data from the ARCADE and ENDYMION studies show seizure frequency reduction over time. In CDD patients, median motor seizure frequency reduction was 24% during the 12-week maintenance period in the ARCADE study, increasing to a 50% reduction in the ENDYMION long-term extension study in the five CDD patients who reached nine months of continuous treatment. In Dup15q patients, there was an increase in median motor seizure frequency in the ARCADE study during the 12-week maintenance period; however, longer-term data from the four Dup15q patients who reached nine months of continuous treatment showed a 74% reduction in median motor seizure frequency. Soticlestat was generally well tolerated in both studies and continues to demonstrate a favorable safety profile. Data reported today are consistent with, and build upon, previous findings with soticlestat. ARCADE is a Phase 2 open-label, signal-finding pilot study designed to inform the potential for future development of soticlestat in CDD and Dup15q. The study enrolled 20 patients, ages 2 to 55 years, with refractory epileptic seizures associated with CDD or Dup15q and consisted of a four- to six-week screening period to establish baseline seizure frequency, followed by a 20-week treatment period, including an eight-week titration/dose optimization period and a 12-week maintenance period. Patients in the study were allowed to be on one to six concomitant anti-epileptic drugs, with the majority of patients concomitantly treated with at least four AEDs, representing a highly refractory patient population. The primary objective of the ARCADE study was to determine percent change from baseline in motor seizure frequency during the 12-week maintenance period. Afterward, patients were offered the chance to continue soticlestat treatment in the ENDYMION open-label extension study, and all patients who completed ARCADE elected to roll over into ENDYMION. ENDYMION is a multi-center, open-label extension study of soticlestat in any patient who has participated in any previous soticlestat DEE clinical study, including patients with CDD, Dup15q, Dravet syndrome and Lennox-Gastaut syndrome. The primary objective of ENDYMION is to assess the long-term safety and tolerability of soticlestat in patients with DEEs and, secondarily, to evaluate the effect of soticlestat on seizure control over time.

ShowHide Related Items >><<
OVID Ovid Therapeutics
$5.98 /

+0.09 (+1.53%)

OVID Ovid Therapeutics
$5.98 /

+0.09 (+1.53%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
OVID Ovid Therapeutics
$5.98 /

+0.09 (+1.53%)

  • 25
    Aug
  • 04
    Oct
OVID Ovid Therapeutics
$5.98 /

+0.09 (+1.53%)

OVID Ovid Therapeutics
$5.98 /

+0.09 (+1.53%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/17/20
09/17
04:55
09/17/20
04:55
ACRS

Aclaris Therapeutics

$2.40 /

+0.05 (+2.13%)

, AUTL

Autolus Therapeutics

$14.03 /

+0.25 (+1.81%)

, EIGR

Eiger BioPharmaceuticals

$10.07 /

+0.13 (+1.31%)

, INO

Inovio

$18.52 /

+4.89 (+35.88%)

, KALA

Kala Pharmaceuticals

$8.61 /

+0.56 (+6.96%)

, OVID

Ovid Therapeutics

$6.61 /

+0.2 (+3.12%)

, PAVM

PAVmed

$1.89 /

+0.01 (+0.53%)

, SLGL

Sol-Gel Technologies

$7.69 /

+0.22 (+2.95%)

, VNRX

VolitionRx

$3.20 /

+0.015 (+0.47%)

, XFOR

X4 Pharmaceuticals

$7.31 /

+0.25 (+3.54%)

, XNCR

Xencor

$41.53 /

+0.66 (+1.61%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$18.52 /

+4.89 (+35.88%)

XNCR Xencor
$41.53 /

+0.66 (+1.61%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/16/20
09/16
04:55
09/16/20
04:55
ACRS

Aclaris Therapeutics

$2.35 /

+0.135 (+6.09%)

, AUTL

Autolus Therapeutics

$13.78 /

-0.01 (-0.07%)

, EIGR

Eiger BioPharmaceuticals

$9.93 /

-0.21 (-2.07%)

, INO

Inovio

$13.63 /

+2.3 (+20.30%)

, KALA

Kala Pharmaceuticals

$8.04 /

+0.05 (+0.63%)

, OVID

Ovid Therapeutics

$6.41 /

+0.17 (+2.72%)

, PAVM

PAVmed

$1.88 /

+0.055 (+3.01%)

, SLGL

Sol-Gel Technologies

$7.47 /

+0.02 (+0.27%)

, VNRX

VolitionRx

$3.18 /

-0.05 (-1.55%)

, XFOR

X4 Pharmaceuticals

$7.09 /

-0.05 (-0.70%)

, XNCR

Xencor

$40.87 /

+0.66 (+1.64%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$13.63 /

+2.3 (+20.30%)

XNCR Xencor
$40.87 /

+0.66 (+1.64%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 08:33
09/15/20
09/15
08:33
09/15/20
08:33
ACRS

Aclaris Therapeutics

$2.25 /

+0.08 (+3.69%)

, AUTL

Autolus Therapeutics

$13.81 /

+1.15 (+9.08%)

, EIGR

Eiger BioPharmaceuticals

$10.11 /

+0.06 (+0.60%)

, INO

Inovio

$11.33 /

+1.235 (+12.23%)

, KALA

Kala Pharmaceuticals

$7.99 /

-0.77 (-8.79%)

, OVID

Ovid Therapeutics

$6.24 /

+0.54 (+9.47%)

, PAVM

PAVmed

$1.83 /

+0.025 (+1.39%)

, SLGL

Sol-Gel Technologies

$7.45 /

-0.03 (-0.40%)

, VNRX

VolitionRx

$3.21 /

+0.06 (+1.90%)

, XFOR

X4 Pharmaceuticals

$7.14 /

-0.81 (-10.19%)

, XNCR

Xencor

$40.21 /

+2.11 (+5.54%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$40.21 /

+2.11 (+5.54%)

XFOR X4 Pharmaceuticals
$7.14 /

-0.81 (-10.19%)

VNRX VolitionRx
$3.21 /

+0.06 (+1.90%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

AUTL Autolus Therapeutics
$13.81 /

+1.15 (+9.08%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$11.33 /

+1.235 (+12.23%)

XNCR Xencor
$40.21 /

+2.11 (+5.54%)

SLGL Sol-Gel Technologies
$7.45 /

-0.03 (-0.40%)

PAVM PAVmed
$1.83 /

+0.025 (+1.39%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

EIGR Eiger BioPharmaceuticals
$10.11 /

+0.06 (+0.60%)

ACRS Aclaris Therapeutics
$2.25 /

+0.08 (+3.69%)

OVID Ovid Therapeutics
$6.24 /

+0.54 (+9.47%)

KALA Kala Pharmaceuticals
$7.99 /

-0.77 (-8.79%)

INO Inovio
$11.33 /

+1.235 (+12.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.